Mangrove Partners Bellus Health Inc. Transaction History

Mangrove Partners

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $5.27 Million - $7.58 Million	-948,221 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $4.99 Million - $7.87 Million	948,221 New	948,221 $7.63 Million
Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $444,644 - $2.5 Million	-207,778 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.88 - $11.15 $2.72 Million - $3.41 Million	-305,906 Reduced 59.55%	207,778 $2.14 Million
Q1 2020 May 15, 2020	BUY	$5.77 - $10.85 $447,169 - $840,864	77,499 Added 17.77%	513,684 $5.13 Million
Q4 2019 Feb 14, 2020	BUY	$5.76 - $7.6 $704,655 - $929,753	122,336 Added 38.98%	436,185 $3.32 Million
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $1.96 Million - $2.77 Million	313,849 New	313,849 $2.01 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.